Grant: Idea to Innovation
University of Windsor
$15,000.00
Market Assessment of Therapeutic Coordination Polymers Containing Pharmaceuticals and Bis-Imidazole Linkers for Drug Release Applications
FY 2021-22
Summary
Considerable time and resources are required to develop new pharmaceuticals and make new medical treatments available. Researchers at the University of Windsor have taken an alternative approach by incorporating existing medications into controlled release materials to improve their performance and speed up their development time. The materials developed are referred to as Therapeutic Coordination Polymers (TCPs), and are constructed from a unique combination of three principal components, i) inorganic metal centers, ii) anionic pharmaceuticals, and iii) small organic molecules which can behave as a "linker" joining the metal centers. More specifically, the team developed a series of biodegradable TCPs with various cationic metal ions, non-steroidal anti-inflammatory drugs (NSAIDs), and various alkyl chain length bis-imidazole linkers. TCPs offer several unique advantages as drug release materials including: i) rapid and scalable synthesis ii) highly consistent drug loading iii) high drug uptake ~60-70 wt%, iv) biocompatibility, and v) most importantly, an extreme degree of control over their drug release rate which can be tailored for desired applications. Whether drugs are taken in the form of a pill or implanted after surgery in the form of a small degradable implant, TCPs could impact several different routes of drug administration. Overall, this research program has broad applications in many areas of drug release and has the potential to make a significant economic benefit and health benefit to the lives of Canadians.
Program
Idea to Innovation
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
570983-2022
Name nom
Vukotic, Vedran
Department département
Chemistry and Biochemistry
Organization id
37
Institution établissement
University of Windsor
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2022
Award amount
15000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
2014
Research subject group en
Materials science and technology
Research subject group fr
Science et technologie des matériaux
Research subject en
Crystal
Research subject fr
Cristaux
Installment
inst:1
Partie
1
Nb partie
1
Application title
Market Assessment of Therapeutic Coordination Polymers Containing Pharmaceuticals and Bis-Imidazole Linkers for Drug Release Applications
Keyword
NSERC
Application summary
Considerable time and resources are required to develop new pharmaceuticals and make new medical treatments available. Researchers at the University of Windsor have taken an alternative approach by incorporating existing medications into controlled release materials to improve their performance and speed up their development time. The materials developed are referred to as Therapeutic Coordination Polymers (TCPs), and are constructed from a unique combination of three principal components, i) inorganic metal centers, ii) anionic pharmaceuticals, and iii) small organic molecules which can behave as a "linker" joining the metal centers. More specifically, the team developed a series of biodegradable TCPs with various cationic metal ions, non-steroidal anti-inflammatory drugs (NSAIDs), and various alkyl chain length bis-imidazole linkers. TCPs offer several unique advantages as drug release materials including: i) rapid and scalable synthesis ii) highly consistent drug loading iii) high drug uptake ~60-70 wt%, iv) biocompatibility, and v) most importantly, an extreme degree of control over their drug release rate which can be tailored for desired applications. Whether drugs are taken in the form of a pill or implanted after surgery in the form of a small degradable implant, TCPs could impact several different routes of drug administration. Overall, this research program has broad applications in many areas of drug release and has the potential to make a significant economic benefit and health benefit to the lives of Canadians.